Pep19 Has a Positive Effect on Insulin Sensitivity and Ameliorates Both Hepatic and Adipose Tissue Phenotype of Diet-Induced Obese Mice
Authors:
- Renata SilvérioRSRenata Silvério
- Robson BarthRBRobson Barth
- Andrea S. HeimannAHAndrea S. Heimann
- Patrícia ReckziegelPRPatrícia Reckziegel
- Gustavo J. dos SantosGSGustavo J. dos Santos
- Silvana Y. Romero-ZerboSRSilvana Y. Romero-Zerbo
- Francisco J. Bermúdez-SilvaFrancisco J. Bermúdez-Silva
- Alex RafachoARAlex Rafacho
- Emer S. FerroEFEmer S. Ferro
Open Access
- 7 April 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (8) , 4082
Abstract
Peptide DIIADDEPLT (Pep19) has been previously suggested to improve metabolic parameters, without adverse central nervous system effects, in a murine model of diet-induced obesity. Here, we aimed to further evaluate whether Pep19 oral administration has anti-obesogenic effects, in a well-established high-fat diet-induced obesity model. Male Swiss mice, fed either a standard diet (SD) or high-fat diet (HFD), were orally administrated for 30 consecutive days, once a day, with saline vehicle or Pep19 (1 mg/kg). Next, several metabolic, morphological, and behavioral parameters were evaluated. Oral administration of Pep19 attenuated HFD body-weight gain, reduced in approximately 40% the absolute mass of the endocrine pancreas, and improved the relationship between circulating insulin and peripheral insulin sensitivity. Pep19 treatment of HFD-fed mice attenuated liver inflammation, hepatic fat distribution and accumulation, and lowered plasma alanine aminotransferase activity. The inguinal fat depot from the SD group treated with Pep19 showed multilocular brown-fat-like cells and increased mRNA expression of uncoupling protein 1 (UCP1), suggesting browning on inguinal white adipose cells. Morphological analysis of brown adipose tissue (BAT) from HFD mice showed the presence of larger white-like unilocular cells, compared to BAT from SD, Pep19-treated SD or HFD mice. Pep19 treatment produced no alterations in mice behavior. Oral administration of Pep19 ameliorates some metabolic traits altered by diet-induced obesity in a Swiss mice model.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2016/04000-3, 2019/25943-1, 2021/02953-1)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (304388/2020-3, 302809/2016-3)
This publication has 95 references indexed in Scilit:
- Application of the UK Foresight Obesity Model in Ireland: The Health and Economic Consequences of Projected Obesity Trends in IrelandPLOS ONE, 2013
- Central functional response to the novel peptide cannabinoid, hemopressinNeuropharmacology, 2013
- Liver Patt1 deficiency protects male mice from age-associated but not high-fat diet-induced hepatic steatosisJournal of Lipid Research, 2012
- CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese MiceDiabetes, 2010
- Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic SteatosisPLOS ONE, 2009
- Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in miceJournal of Clinical Investigation, 2008
- Hepatic Insulin Resistance Is Sufficient to Produce Dyslipidemia and Susceptibility to AtherosclerosisCell Metabolism, 2008
- Hemopressin is an inverse agonist of CB 1 cannabinoid receptorsProceedings of the National Academy of Sciences, 2007
- Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese menInternational Journal of Obesity, 2007
- Blockade by the Cannabinoid CB1 Receptor Antagonist, Rimonabant (SR141716), of the Potentiation by Quinelorane of Food-Primed Reinstatement of Food-Seeking BehaviorNeuropsychopharmacology, 2003